News archive
308 results
-
Fimea’s final accounts and annual report for 2017 have been published
-
Cost-effectiveness included as part of the assessment of new hospital-only medicinal products
-
Updated recommendations for safety limits for menthofuran and pulegone
-
Fimea published a rapid review of orphan medicinal product sebelipase alfa
-
Fimea as a reference member state (RMS) for marketing authorisation applications
-
Finnish National Medicines Day 2018 viewpoints opened by Minister Pirkko Mattila
-
Fimea to arrange a Horizon Scanning event for pharmaceutical companies on 10 April 2018
-
A study on biosimilars begins
Showing 301 - 308 / 308